Initial results from a Phase II study (TACTI-002) in non-small cell lung cancer, or head and neck cancer patients receiving eftilagimod alpha (LAG-3 fusion protein) and pembrolizumab
Peguero, J Felip, E Doger, B Majem, M Carcereny, E Clay, T Bajaj, P Krebs, Matthew G Triebel, F
Peguero, J
Felip, E
Doger, B
Majem, M
Carcereny, E
Clay, T
Bajaj, P
Krebs, Matthew G
Triebel, F
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Peguero J, Felip E, Doger B, Majem M, Carcereny E, Clay T, et al. Initial results from a Phase II study (TACTI-002) in non-small cell lung cancer, or head and neck cancer patients receiving eftilagimod alpha (LAG-3 fusion protein) and pembrolizumab. Journal for Immunotherapy of Cancer. 2019;7